ERBB2 and gastric cancer: However, since the publication of the pivotal ToGA trial which established the combination of fluoropyrimidine-cisplatin plus trastuzumab as the standard of care in treatment-naïve patients with HER2-positive metastatic GC, a plethora of negative trials on HER2 targeted therapies in GC patients have been presented or published [16]; in fact, the LOGiC, TyTAN, JACOB, and GATSBY trials on lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1) failed to meet their primary endpoints [17,18,19,20] (Table 2).